SecBot SecBot
PRESS-RELEASE ·Filed Aug 12, 2026

ABUS

Arbutus Biopharma Corporation
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The capital return plan (up to ~$230M) and the Moderna settlement cash provide a significant floor for the stock. Monitor for the specific form of share repurchases (tender offer vs open market) and any updates on the Pfizer/BioNTech LNP lawsuits, which could unlock additional value. The operational quarter is irrelevant, trade on the capital allocation and litigation catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

ABUS drug pipeline →

AB-101

● Neutral Named in this press release
Impact
Phase
Phase 1a/1b
Time to market
AB-101 is in Phase 1a/1b trials; even if development proceeds smoothly, a potential approval is likely several years away given the early stage and the need for larger Phase 2 and Phase 3 trials.
Next catalyst
None dated

What to watchThe next catalyst for ABUS is Q3 2026 earnings on November 11, 2026 (tomorrow), which may include updates on AB-101's clinical development plans now that the FDA hold is lifted. For AB-101 specifically, watch for the company to announce the next phase of clinical trials in chronic hepatitis B patients. The clinical hold lift removes a key overhang, but the drug remains early-stage with no pivotal readout or PDUFA date on the horizon.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.59
T+0 close · Aug 12, 2026 · via day close
Latest settled
−20.04%
T+60 · $3.67
Vs SPY
−14.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 12 $4.59entry
  2. T+1 · 3mo ago −0.22%α −0.92% · $4.58
  3. T+5 · 3mo ago +8.50%α +8.94% · $4.98
  4. T+20 · 2mo ago +11.55%α +13.44% · $5.12
  5. T+60 · 12d ago −20.04%α −14.93% · $3.67
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arbutus Biopharma reported Q2 2026 revenue of $1.0M (down from $10.7M YoY due to the prior year's Qilu partnership revenue recognition) and a net loss of $5.1M (-$0.03 EPS), in line with consensus. The quarter was overshadowed by the receipt of $178.4M from the Moderna settlement in July and a plan to return up to ~$230M to shareholders via share repurchases, alongside new LNP patent lawsuits against Pfizer/BioNTech. The stock will move on the capital return plan and litigation catalysts, not the operational results.

Key Financial Metrics

EPS
−$0.03
est −$0.03 · 0.0%
Revenue
$1.0M
est $961.0K · +5.5% · -90.6% YoY
Rating
in line

Key Facts

  • Received $178.4M from Moderna settlement in July 2026 as share of $950M noncontingent payment
  • Plans to return up to ~$230M to shareholders via share repurchases, potentially including a Dutch Auction tender offer
  • Filed three international LNP patent lawsuits against Pfizer/BioNTech across 21 countries
  • Q2 2026 revenue $1.0M vs $10.7M YoY; net loss $5.1M (-$0.03 EPS) vs net income $2.5M ($0.01 EPS) YoY
  • Cash and marketable securities $92.6M as of June 30, 2026, plus $179.4M receivable from Genevant license
  • FDA Fast Track designation for imdusiran in chronic hepatitis B; alignment on Phase 2b trial design

Financial Impact

Capital return of up to ~$230M (25% of current market cap) plus $178.4M cash infusion from Moderna settlement

cashshare countlitigation exposure

Risk Factors

  • Capital return plan is subject to board approval and may not occur in Q3 2026 or at all
  • Pfizer/BioNTech lawsuits face uncertain outcomes and could be protracted
  • Imdusiran Phase 2b trial may not meet endpoints or receive regulatory approval
  • Contingent $1.3B Moderna payment depends on appellate ruling on 28 U.S.C. §1498

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3343555

Track record

25 reports on ABUS

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +7.42% at T+60 after the May 13, 2026 report. 5 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
  3. Nov 16, 2026today SC 13G Neutral 3/10 Entry $4.07 Now $4.04 −0.74% settles Feb 12
  4. Nov 12, 20264d ago 8-K Neutral 2/10 Entry $4.03 Now $4.04 +0.25% settles Feb 10
  5. Nov 10, 20266d ago 8-K Neutral 5/10 Entry $3.82 Now $4.04 +5.76% settles Feb 8
  6. Nov 10, 20266d ago Press Release Neutral 4/10 No price data
  7. Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $3.66 Now $4.04 −10.53% settles Feb 4
  8. Oct 22, 202625d ago 8-K Bullish 6/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
  9. Oct 22, 202625d ago Press Release Bullish 7/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
  10. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $4.18 Now $4.04 −3.35% settles Jan 5
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 12, 2026